A phase II study of chemoradiotherapy with use of involved-field conformal radiotherapy and accelerated hyperfractionation for Stage III non-small cell lung cancer - A phase II study of chemoradiotherapy with IF-RT and AHF for Stage III NSCLC

West Japan Oncology Group0 个研究点目标入组 44 人开始时间: 2013年4月5日最近更新: 2023年10月17日

适应症

试验速览

暂无简介。

•(1)Chest CT shows active interstitial pneumonia or pulmonary fibrosis or severe pulmonary emphysema. (2)The patient has SVC syndrome. (3)The patient has one or more nodal metastases as listed below; supraclavicular node, anterior scalene node, contralateral hilar node. These nodes are assumed as positive if they are FDG/PET positive and have more than 5mm diameter. Malignant pleural effusion, malignant pericardial effusion and malignant lymphangitis are also ineligible. (4)The patient has a history of previous thoracic radiotherapy. (5)The patient has active previous or concomitant malignancies. (6)The patient has uncontrolled diabetes mellitus. (7) The patients has active local or systemic infection, which should be treated. (8)The patient has a severe complication (ex.gastrointestinal bleeding, heart disease, glaucoma, HIV infection). (9) The patient has a history of allergy against agents containing polyoxyethilene oil or severe drug allergy. (10) The patient has psychiatric disorders that may comprise the patient s ability to comply with the study. (11) Positive serum HBs antigen or HCV antibody. (12) The patient is pregnant, may be pregnant, or is lacting. The patient, if is of child-bearing potential, does not practice contraception. (13) In the view of the investigator, the patient can and will comply with the requirement of the protocol.

发起方